ReAcT CO2: A Study to Assess TcCO2 to Guide Acute NIV (ReAcTCO2)

Noninvasive Monitoring for Noninvasive Ventilation: Use of Transcutaneous Carbon Dioxide Monitoring to Guide Acute Noninvasive Ventilation in Patients With Acute Hypercapnic Respiratory Failure: A Multicenter Study

Arterial blood sampling is needed to monitor carbon dioxide and PH but is often painful. The aim of this study is to determine whether continuous carbon dioxide monitoring with a skin probe reduces the need for arterial blood sampling by at least 30%. The investigators will also study the safety and effectiveness of skin probe monitoring to manage non-invasive ventilation (NIV).

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Hypercapnic Respiratory Failure
• Intervention / Treatment: Other: Arterial Blood Gas (ABG) sampling; Device: Trancutaneous CO2 monitoring (using TCM5 device)

Detailed Description

Patients with breathing difficulty need arterial blood sampling to check carbon dioxide levels. This is difficult, painful, associated with complications and often met with delays. The investigators have shown in a previous observational study, that using a skin probe to monitor carbon dioxide levels in patients with acute breathing difficulty was far more comfortable, significantly less painful and importantly closely reflected arterial carbon dioxide levels. Decisions regarding breathing support with mask (noninvasive ventilation or NIV) were however based on arterial blood samples collected simultaneously.

In this feasibility study over 72 hours, patients will either have arterial blood sampling or skin probe to monitor carbon dioxide levels.

The aim of the study is to determine whether continuous carbon dioxide monitoring with a skin probe reduces the need for arterial blood sampling by at least 30%. Investigators will also study the safety and effectiveness of skin probe monitoring to manage NIV.

Towards this the investigators will study patients admitted with sudden worsening of breathing that has led to a build up of carbon dioxide. Patients will be recruited within 8 hours, although preferably within 4 hours of starting NIV, preferably in the Emergency Department(ED). Their carbon dioxide levels will then be monitored by skin probe (TcCO2 group) or arterial blood gas (ABG) sampling.

Clinicians can perform ABGs in TcCO2 group at their discretion. Our main end point is the total number of ABGs performed in each group. Clinicians will complete a questionnaire for unscheduled ABGs in TcCO2 group.

The investigators will also measure any side effects, pain experienced by patients in each group and ease of using each technique as well as explore barriers to using transcutaneous monitoring and identify any drawbacks of this method.

• Study Type: Interventional
• Enrollment (Anticipated): 60
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients aged18 years and over with hypercapnia, requiring acute NIV and who are admitted to the Emergency Department or Medical HDU and, who need arterial blood sampling for clinical reasons.
• Recruited ideally within 4 hours (but no later than 8 hours) of initiation of acute NIV in hospital.

Exclusion Criteria:

• Reduced level of consciousness or agitation.
• Metabolic or mixed acidosis, serum bicarbonate < 24 mmol/L.
• Haemodynamic instability or reduced skin perfusion.
• Patients requiring more than 6litres/min (ormorethan60%) inspired oxygen through ventilator to maintain SpO2 of 88-92%.
• Need for multi-organ support e.g. inotropes or vasopressors or renal replacement therapy
• Arterial pH equal or less than 7.1 or carbon dioxide levels >15kPa as they are at risk of NIV failure and likely to require mechanical ventilation.
• Participating in any other interventional study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Arterial Blood Gas (ABG) arm - Control arm; Patients in this arm will undergo arterial blood gas sampling to monitor CO2 as per the British Thoracic Society guidance which is standard practice.	Other: Arterial Blood Gas (ABG) sampling; Arterial Blood Gas (ABG) sampling to monitor CO2 - as per standard practice.
Experimental: transcutaneous CO2 arm; Patients in this arm will undergo transcutaneous monitoring to monitor CO2. This will be the experimental arm.	Device: Trancutaneous CO2 monitoring (using TCM5 device); Patients in the Transcutaneous arm will undergo Trancutaneous CO2 monitoring (using TCM5 device)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Average number of arterial blood gases per participant over the study period	the total (Scheduled and unscheduled) arterial blood samples over 72 hours per participant in each group .	over the study period of 72 hours per participant
number of unscheduled arterial blood sample in each group	arterial blood sampling needed for clinical deterioration or due to unreliability of transcutaneous CO2 monitoring for each patient	over the study period of 72 hours per participant
number of instances where transcutaneous monitoring was unreliable and arterial blood gas sampling was needed.	Clinicians will complete questionnaires regarding the need for unscheduled arterial blood samples and changes in management due to these incidences of arterial blood sampling in the transcutaneous monitoring group.	over the total study period of 72 hours per patient

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain and any discomfort from arterial blood sampling and transcutaneous monitoring using a visual analogue scale from 0 to 10 with 0 being no pain and 10 being the worst pain they have ever experienced	Pain and any discomfort (such as skin burns, blisters, erythema, bruising or restriction of physical activity) from arterial blood sampling and transcutaneous monitoring	over the study period of 72 hours per participant
Proportion of patients admitted with acute hypercapnic respiratory failure that are suitable and agree to participate in the study over one year (to help guide future studies).	Suitability and feasibility	Over the total study period of 1 year.
Proportion of patients who achieve 50% drop in carbon dioxide in 12 hours and those who achieve carbon dioxide level of 7 kPa or less in 72 hours in each group.	Proportion of patients who achieve 50% drop in carbon dioxide in 12 hours and those who achieve carbon dioxide level of 7 kPa or less in 72 hours in each group.	over the study period of 72 hours per participant
Proportion of patients who need further changes to ventilator settings beyond 4 hours and 24 hours	How quickly can we optimise NIV settings	over the study period of 72 hours per participant
Proportion of patients with deterioration in CO2 at 4 and 24 hours after NIV initiation	Can TcCO2 identify deteriorating patients quicker	over the study period of 72 hours per participant
Proportion of patients who get better and are discharged and proportion that fail to respond and either need mechanical ventilation / progress to palliative care.	Proportion of patients who get better and are discharged and proportion that fail to respond and either need mechanical ventilation / progress to palliative care.	over the study period of 72 hours per participant
Transcutaneous arm only - agreement between arterial and transcutaneous readings:	a) absolute CO2 values obtained within 30 minutes of each other will be tested using Bland Altman plot; b) trend between serial ABG CO2 values and transcutaneous CO2 readings when ABGs performed (scheduled and unscheduled ABG will be assessed separately).	over the study period of 72 hours per participant
Discrete choice: what method would patients prefer for monitoring during similar future illness requiring NIV?	Do patients prefer one method of monitoring over the other. This is reasonable to ask all those randomized to TcCO2 as they will experience both ABG and TcCO2	over the study period of 72 hours per participant
Clinician Preference questionnaire: whether they prefer ABG versus transcutaneous CO2 monitoring	Taking into consideration time and difficulty, plus certainty of implementing changes to NIV settings and weaning, with respect to modality of carbon dioxide monitoring.	over the total study period of 1 year
Time needed to wean off NIV in each group i.e. time from documented clinician decision to wean, until time of cessation of NIV.	This would help assess whether transcutaneous CO2 monitoring allows for quicker weaning from NIV.	over the study period of 72 hours per participant
Basic Health economics data will be gathered to assess whether transcutaneous monitoring is a cost effective way compared to arterial blood gas sampling.	Cost effectiveness of the two methods to monitor CO2	over the total study period of 1 year

Collaborators and Investigators

• Sponsor: Nottingham University Hospitals NHS Trust

Study record dates

Study Major Dates

• Study Start (Anticipated): February 10, 2023
• Primary Completion (Anticipated): February 7, 2024
• Study Completion (Anticipated): February 10, 2024

Study Registration Dates

• First Submitted: December 15, 2022
• First Submitted That Met QC Criteria: December 29, 2022
• First Posted (Estimate): January 6, 2023

Study Record Updates

• Last Update Posted (Estimate): January 6, 2023
• Last Update Submitted That Met QC Criteria: December 29, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Signs and Symptoms, Respiratory; Respiratory Insufficiency; Hypercapnia
• Other Study ID Numbers: 18RM021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No